Lemaitre Vascular stock hits 52-week low at 78.64 USD
LeMaitre Vascular Inc. (LMAT) hit a 52-week low of $78.64, down 16.96% over the past year. The company reported Q2 earnings of $0.74 per share on $70.4M revenue, missing estimates. LMAT revised its full-year outlook downward but maintains strong fundamentals, with a PEG ratio of 0.71. InvestingPro suggests the stock is undervalued.
How this was made
The 30-second read
Why it matters
Earnings miss and outlook cut could trigger short‑term sell pressure.
Market read
Small‑cap earnings miss with modest scale; limited broader market impact.
What to watch
Strong balance sheet and health score may support resilience despite earnings miss.
Background
LeMaitre Vascular is a medical device manufacturer listed on Nasdaq.
Ticker impact
Q2 earnings miss: adjusted EPS $0.74 vs $0.81 est, revenue $70.4M vs $71.47M est, full-year outlook cut.
Potential further downside until guidance clarity.
Missed estimates and lowered outlook suggest near-term weakness for a small-cap medical device stock.
Market effects
May weigh on other med‑device peers as earnings pressure spreads.
Limited to US small‑cap segment.
Low
Counterpoint
Valuation still attractive with PEG 0.71; could be a buying opportunity on dip.
Key entities
- CompanyLeMaitre Vascular Inc.
Medical device maker reporting Q2 results.
